No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
490 |
4. Check minimum number of eventsNone |
490 |
5. Include endpointsNone |
490 |
6. Filter based on genotype QC (FinnGen only) |
490 |
Control definitions (FinnGen only)
- Control exclude
- D3_COAGDEF_PURPUR_HAEMORRHAGIC
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D68
- Name in latin
- Morbus von Willebrand
Similar endpoints
↥List of similar endpoints to
Von Willebrand disease
based on the number of shared cases.
Similar with more cases:
- Other coagulation defects
- Coagulation defects, purpura and other haemorrhagic conditions
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3361 | 2297 | 1052 |
| Only index persons | 3158 | 2208 | 950 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.05 | 0.07 | 0.03 |
| Only index persons | 0.07 | 0.08 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 28.87 | 33.42 | 18.84 |
| Only index persons | 28.84 | 33.23 | 18.62 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 490 | 413 | 77 |
| Unadjusted period prevalence (%) | 0.12 | 0.14 | 0.03 |
| Median age at first event (years) | 37.08 | 36.97 | 37.73 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 441
- Matched controls
- 4410
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D68.0
ICD-10 Finland
Von Willebrand disease
+∞
323.0
428
*
B02AA02
ATC
tranexamic acid; systemic
21.5
172.7
325
508
126
Kela drug reimbursment
Chronic coagulation defects
+∞
132.0
120
*
D68.9
ICD-10 Finland
Coagulation defect, unspecified
+∞
53.2
50
*
O99.1
ICD-10 Finland
Other diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism complicating pregnancy, childbirth and the puerperium
102.4
42.7
46
5
D68.8
ICD-10 Finland
Other specified coagulation defects
154.2
40.5
42
*
2864A
ICD-9 Finland
Coagulation defects, von Willebrand's disease
+∞
34.8
33
*
D69.9
ICD-10 Finland
Haemorrhagic condition, unspecified
363.5
34.4
34
*
28630
ICD-8 Finland
Coagulation defects, Vascular haemophilia
+∞
25.2
24
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
13.6
23.1
40
32
N02AX02
ATC
tramadol; systemic, rectal
2.7
20.7
214
1150
EBA10
NOMESCO Finland
Surgical removal of tooth
3.5
20.3
109
380
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
6.3
20.0
55
98
N92.0
ICD-10 Finland
Excessive and frequent menstruation with regular cycle
3.6
19.0
96
318
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.5
18.9
236
1388
D68.2
ICD-10 Finland
Hereditary deficiency of other clotting factors
+∞
16.8
16
*
N02BE01
ATC
paracetamol; systemic, rectal
3.3
16.5
397
3219
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
5.0
16.5
55
123
R79.8
ICD-10 Finland
Other specified abnormal findings of blood chemistry
34.8
15.9
20
6
R04.0
ICD-10 Finland
Epistaxis
5.9
15.3
43
79
M01AE01
ATC
ibuprofen; systemic, rectal
0.4
14.2
297
3677
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.2
12.9
197
1202
2BD06
NOMESCO Finland
NA
+∞
12.6
12
*
N02AJ06
ATC
codeine and paracetamol; systemic
2.1
12.0
186
1130
WZB00
NOMESCO Finland
Telephone receipt or other advice
2.1
11.5
165
967
Z35.8
ICD-10 Finland
Supervision of other high-risk pregnancies
2.9
10.6
69
268
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.0
10.6
172
1051
D66
ICD-10 Finland
Hereditary factor VIII deficiency
112.5
10.5
11
*
D69.1
ICD-10 Finland
Qualitative platelet defects
+∞
10.5
10
*
194
Kela drug reimbursment
Blood coagulation factor VIII and von Willebrand factor for the treatment of von Willebrand disease
+∞
10.5
10
*
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
3.7
10.4
46
135
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.1
10.1
131
728
TLC00
NOMESCO Finland
Insertion of intrauterine device
3.0
9.8
59
217
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
56.2
9.7
11
*
R79.9
ICD-10 Finland
Abnormal finding of blood chemistry, unspecified
30.7
9.4
12
*
J01DB01
ATC
cefalexin; oral
2.2
9.4
374
3150
R51.80
ICD-10 Finland
Headache
2.3
9.3
94
462
Z71.8
ICD-10 Finland
Other specified counselling
2.1
9.1
130
746
SAA03
NOMESCO Finland
Extended examination of mouth
1.9
9.0
203
1379
K04.5
ICD-10 Finland
Chronic apical periodontitis
2.1
8.8
117
650
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.0
8.6
139
833
UJF32
NOMESCO Finland
Coloscopy
2.1
8.5
112
619
D69.0
ICD-10 Finland
Allergic purpura
+∞
8.4
8
*
B02BD06
ATC
von Willebrand factor and coagulation factor VIII in combination; parenteral, topical, urethral
+∞
8.4
8
*
B02BD02
ATC
coagulation factor VIII; parenteral, topical, urethral
+∞
8.4
8
*
R42
ICD-10 Finland
Dizziness and giddiness
2.2
8.3
96
501
J01FA10
ATC
azithromycin; systemic
1.8
8.3
290
2259
G43.9
ICD-10 Finland
Migraine, unspecified
2.9
8.2
49
181
ZX120
NOMESCO Finland
Intravenous
2.8
8.1
54
211
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
8.1
162
1047
J01.0
ICD-10 Finland
Acute maxillary sinusitis
2.0
8.1
130
776
H02AB06
ATC
prednisolone; systemic
1.8
7.9
207
1460
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
5.2
7.8
23
46
R01AD12
ATC
fluticasone furoate; nasal
1.8
7.6
163
1074
C01CA24
ATC
epinephrine; parenteral
2.9
7.6
47
175
AA1AD
NOMESCO Finland
CT of head and brain
2.1
7.5
90
476
R03AC02
ATC
salbutamol; inhalant
1.7
7.4
248
1871
N03AX16
ATC
pregabalin; oral
2.0
7.4
108
620
N03AX12
ATC
gabapentin; oral
2.3
7.4
74
362
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
2.3
7.4
67
313
N92.1
ICD-10 Finland
Excessive and frequent menstruation with irregular cycle
2.8
7.4
47
181
M25.5
ICD-10 Finland
Pain in joint
1.8
7.3
141
893
9981A
ICD-9 Finland
Other complications of procedures, not elsewhere classified, Haemorrhage or haematoma complicating a procedure
16.0
7.3
11
7
Z00.0
ICD-10 Finland
General medical examination
2.0
7.0
91
499
R07.4
ICD-10 Finland
Chest pain, unspecified
2.0
7.0
101
574
J01FF01
ATC
clindamycin; systemic
1.9
6.9
120
734
S06.0
ICD-10 Finland
Concussion
2.5
6.8
54
236
Z01.8
ICD-10 Finland
Other specified special examinations
1.9
6.8
103
597
N92.6
ICD-10 Finland
Irregular menstruation, unspecified
2.6
6.7
49
203
Z35.9
ICD-10 Finland
Supervision of high-risk pregnancy, unspecified
3.5
6.7
29
86
Z31.5
ICD-10 Finland
Genetic counselling
2.9
6.6
39
144
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.7
6.5
237
1806
N02CC01
ATC
sumatriptan; nasal, systemic, rectal
2.0
6.5
93
529
G47.3
ICD-10 Finland
Sleep apnoea
2.0
6.4
85
468
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.2
6.4
63
305
P01AB01
ATC
metronidazole; oral, rectal
1.7
6.4
195
1411
J01MA02
ATC
ciprofloxacin; systemic
1.7
6.3
148
992
2BDXX
NOMESCO Finland
NA
+∞
6.3
6
*
O991, D680
ICD-10 Finland
NA
+∞
6.3
6
*
D68.1
ICD-10 Finland
Hereditary factor XI deficiency
+∞
6.3
6
*
X59
ICD-10 Finland
Exposure to unspecified factor
2.0
6.3
84
466
EB1AA
NOMESCO Finland
Tooth X-ray examination
1.7
6.2
252
1966
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.7
6.2
192
1391
J01DA01
ATC
[U] cefalexin; systemic
1.7
6.2
280
2253
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.0
6.2
78
423
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.2
6.1
65
326
SPAT1263
SPAT
Sampling
1.7
6.1
185
1333
SHB00
NOMESCO Finland
Prepation and fitting of bite rail to mouth
2.1
6.0
69
358
J06.9
ICD-10 Finland
Acute upper respiratory infection, unspecified
1.6
6.0
227
1733
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
189
7
437.57
201.53
5.6
1.3
83.3
152.7
%
—
177
7
258
475
10.36
152.65
3.6
1.9
30.9
29.2
s
4.51
248
458
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
63
14
51.49
108.08
1.3
1.0
116.6
138.9
%
0.94
56
14
59
14
47.77
99.57
1.2
1.0
94.6
96.4
%
—
26
8
110
114
12.15
98.66
4.3
2.9
98.0
97.4
%
0.09
110
104
57
14
45.94
95.34
1.2
1.0
100.7
104.5
%
—
26
8
45
0
+∞
47.69
1.5
0.0
51.2
—
%
—
39
0
108
287
4.54
38.00
2.7
2.3
85.3
75.0
ml/min/173m2
1.85
84
101
138
470
3.70
34.13
4.2
2.1
2.5
2.5
g/l
0.03
133
429
144
523
3.48
32.05
4.2
2.1
14.7
14.0
umol/l
0.56
139
475
204
926
3.06
31.05
3.2
1.8
0.6
0.8
mg/l
1.97
154
698
269
1469
2.84
28.39
5.0
4.1
37.3
36.5
g/l
1.56
252
1375
148
622
2.98
25.03
3.5
2.5
2.4
2.4
mmol/l
0.49
141
543
234
1285
2.57
23.03
3.4
3.0
2.4
2.4
mmol/l
0.41
220
1144
186
950
2.54
20.90
4.0
2.0
2.9
3.0
mg/l
0.20
166
810
394
2982
2.64
16.65
7.6
6.6
75.2
76.9
u/l
0.40
378
2805
285
1913
2.17
15.49
5.2
5.5
10.5
9.8
umol/l
0.22
268
1807
329
2353
2.21
14.99
9.1
8.7
3.9
3.9
e9/l
0.01
302
2056
264
1737
2.13
14.91
6.4
5.8
1.2
1.2
mmol/l
0.26
227
1467
387
3010
2.36
13.61
4.6
3.9
9.3
10.3
mm/h
0.85
370
2790
239
1551
2.06
13.61
5.4
5.2
1.2
1.2
mmol/l
0.02
223
1414
12
0
+∞
12.55
1.4
0.0
—
—
—
0
0
200
1273
1.96
11.51
2.8
2.8
—
—
—
0
0
289
2084
1.94
11.42
4.7
2.8
91.5
74.6
ug/l
0.98
274
1943
291
2130
1.90
10.70
4.3
3.9
6.3
6.5
mmol/l
1.11
274
1940
466
4122
3.66
9.94
15.8
11.0
19.8
20.2
mg/l
0.10
408
3142
157
972
1.91
9.45
2.6
2.7
0.3
0.4
e6/l
0.13
125
700
399
3368
1.99
8.15
5.5
4.1
14.5
14.5
pmol/l
0.31
384
3126
249
1894
1.64
6.69
5.7
3.8
—
—
—
0
0
162
1142
1.63
5.70
2.4
2.3
54.0
57.4
u/l
0.77
151
1059
85
502
1.84
5.66
2.2
1.7
—
—
—
0
0
190
1402
1.58
5.48
1.9
1.8
103.5
97.7
pmol/l
0.69
97
721
172
1244
1.59
5.38
2.9
3.0
22.2
62.3
ng/l
0.60
87
693
226
1741
1.55
5.36
2.8
2.3
75.3
76.1
nmol/l
0.16
215
1587
113
738
1.69
5.30
2.5
2.9
1304.2
794.6
ng/l
0.61
93
619
58
309
1.99
5.25
1.4
1.2
78.4
224.5
u/ml
1.18
53
288
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
20
65
3.17
5.12
3.4
3.3
0.2
0.4
u/ml
3.18
15
33
55
294
1.98
4.93
3.3
3.7
4.5
4.7
pmol/l
0.87
48
261
55
294
1.98
4.93
5.7
7.4
5.3
5.2
kpa
0.33
55
282
468
4367
2.60
4.88
12.4
9.0
25.2
25.0
u/l
0.08
463
4240
433
3928
1.88
4.86
6.3
4.8
1.8
2.1
mu/l
0.43
416
3679
251
2007
1.51
4.85
4.3
3.3
0.0
0.0
estimate
0.00
61
401
149
1065
1.57
4.82
1.8
1.6
—
—
—
0
0
149
1070
1.56
4.70
4.8
3.5
0.0
0.0
estimate
0.50
65
407
421
3803
1.76
4.57
14.4
9.9
89.9
88.4
ml/min/173m2
0.73
377
3067
152
1105
1.54
4.52
1.4
1.3
0.6
1.5
u/ml
1.38
54
309
60
342
1.86
4.46
2.0
1.7
—
—
—
0
0
43
221
2.04
4.31
1.6
1.5
—
—
—
0
0
312
2651
1.49
4.22
5.2
4.0
224.9
1439.0
e6/l
—
7
43
177
1349
1.49
4.15
2.8
2.9
27.0
29.2
u/l
0.71
170
1290
52
293
1.87
4.01
5.8
7.5
0.9
1.4
mmol/l
0.35
41
237
201
1581
1.46
3.98
4.5
3.3
—
—
—
0
0
50
279
1.88
3.98
3.9
3.5
1.2
1.2
mmol/l
0.03
45
236
127
911
1.53
3.95
2.9
2.0
—
—
—
0
0
112
788
1.55
3.79
1.3
1.3
38.4
14.1
u/ml
0.29
44
321
57
337
1.78
3.78
1.9
1.7
—
—
—
0
0
8
12
6.76
3.68
2.8
2.5
60.8
90.2
ug/l
—
8
12
248
2050
1.42
3.66
4.3
3.3
0.0
0.0
estimate
0.80
65
392
67
419
1.69
3.65
2.4
2.7
9.6
7.3
umol/l
0.17
57
357
12
35
3.49
3.64
1.7
1.9
90.6
91.6
%
0.24
12
35
245
2026
1.42
3.58
5.6
4.5
0.0
0.0
estimate
0.50
64
404
364
3236
1.49
3.57
3.7
3.6
—
—
—
0
0
122
894
1.49
3.38
3.0
2.5
318.8
5602.4
umol/l
3.64
108
788
9
19
4.80
3.25
1.0
1.1
1845.9
1744.4
miu/ml
—
9
19
19
79
2.46
3.17
1.1
1.1
—
—
—
0
0
324
2847
1.41
3.16
3.0
2.9
39.0
39.0
u/l
0.00
302
2708
111
809
1.48
3.14
1.4
1.3
27.4
30.4
iu/ml
0.08
33
268
88
612
1.53
3.11
3.3
3.1
495.8
256.3
ng/l
0.27
48
384
19
80
2.43
3.10
1.5
1.6
—
—
—
0
0
119
882
1.46
3.09
4.9
3.4
1.0
1.0
kg/l
0.69
18
117
29
147
2.03
3.06
1.7
1.3
13.5
11.5
u/l
0.16
22
118
34
183
1.92
3.05
1.5
1.3
—
—
—
0
0
18
75
2.45
3.00
1.5
1.7
—
—
—
0
0
136
1044
1.42
2.91
1.6
1.6
1.6
1.3
mmol/l
1.79
118
907
18
77
2.39
2.85
4.6
3.9
57.4
57.2
%
0.02
18
77
80
557
1.52
2.82
2.5
2.4
0.6
1.1
e6/l
2.05
47
292
20
94
2.18
2.58
1.5
1.5
—
—
—
0
0
14
57
2.50
2.47
1.6
1.6
—
—
—
0
0
17
76
2.28
2.47
3.8
3.5
4.6
4.4
e9/l
0.10
17
76
53
348
1.59
2.42
3.3
2.9
—
—
—
0
0
28
154
1.87
2.39
1.9
1.8
—
—
—
0
0
14
59
2.41
2.31
1.6
1.8
—
—
—
0
0
46
296
1.61
2.29
2.3
2.3
4450.5
4019.1
u/l
0.04
15
133
12
47
2.59
2.28
1.7
1.6
—
—
—
0
0
10
36
2.81
2.21
1.4
1.1
0.5
0.1
u/ml
—
5
8
42
267
1.63
2.20
3.3
3.5
80.7
69.8
ng/l
0.37
37
241
74
534
1.45
2.20
2.5
2.5
2.2
3.6
e6/l
1.53
41
268
480
4662
2.45
2.19
27.0
16.7
133.8
134.1
g/l
0.17
480
4610
25
137
1.87
2.17
1.7
1.3
—
—
—
0
0
51
342
1.55
2.15
2.1
2.4
30.0
32.3
u/l
0.28
45
295
25
138
1.86
2.13
1.5
1.1
—
—
—
0
0
36
223
1.66
2.09
1.8
1.6
—
—
—
0
0
58
403
1.50
2.08
2.3
1.7
—
—
—
0
0
12
50
2.44
2.04
1.6
1.5
—
—
—
0
0
24
133
1.85
2.03
3.0
1.8
—
—
—
0
0
11
44
2.53
2.02
1.2
1.1
—
—
—
0
0
16
78
2.09
1.93
9.2
4.1
3.8
3.8
mmol/l
0.03
16
70
8
28
2.89
1.87
1.9
1.6
—
—
—
0
0
6
17
3.56
1.84
1.0
1.4
—
—
—
0
0
423
4008
1.41
1.83
4.3
3.9
4.7
4.8
mmol/l
0.35
397
3769
9
35
2.60
1.81
1.8
1.5
—
—
—
0
0
69
513
1.40
1.76
2.4
1.9
—
—
—
0
0
15
75
2.03
1.71
1.3
1.1
—
—
—
0
0
33
212
1.60
1.70
2.4
2.2
4.3
5.6
ug/l
0.30
28
188
55
397
1.43
1.66
1.3
1.2
162.4
155.2
iu/ml
0.04
21
167
14
69
2.06
1.66
1.3
1.2
6.7
3.6
u/ml
—
6
26
22
128
1.75
1.63
2.9
1.7
—
—
—
0
0
5
14
3.60
1.62
1.8
4.1
—
—
—
0
0
10
43
2.35
1.61
1.8
1.6
—
—
—
0
0
13
63
2.09
1.61
1.2
1.1
—
—
—
0
0
7
26
2.72
1.58
1.9
1.6
—
—
—
0
0
7
26
2.72
1.58
1.9
1.6
—
—
—
0
0
7
26
2.72
1.58
1.9
1.6
—
—
—
0
0
6
20
3.02
1.58
2.3
1.4
14.2
25.8
ug/l
—
6
20
25
153
1.67
1.56
1.3
1.9
—
—
—
0
0
26
162
1.64
1.52
1.5
1.6
—
—
—
0
0
6
21
2.88
1.51
1.0
1.0
—
—
—
0
0
6
21
2.88
1.51
2.7
3.1
—
—
—
0
0
103
837
1.29
1.48
2.2
2.1
—
—
—
0
0
16
87
1.87
1.47
1.2
1.3
—
—
—
0
0
11
52
2.14
1.45
1.6
1.7
—
—
—
0
0
23
141
1.66
1.44
1.8
2.0
2.0
6.0
iu/l
2.76
11
50
5
16
3.15
1.44
1.0
1.4
—
—
—
0
0
24
149
1.64
1.44
1.5
1.4
1.1
1.2
g/l
1.65
24
144
424
4053
1.34
1.43
4.6
4.2
2.8
2.9
mmol/l
0.40
398
3787
23
142
1.65
1.41
1.4
1.5
0.2
0.2
g/l
1.58
23
137
418
3990
1.32
1.40
4.2
3.8
1.5
1.5
mmol/l
2.05
391
3736
94
762
1.29
1.38
2.2
2.0
—
—
—
0
0
14
75
1.89
1.35
1.7
4.7
—
3.1
—
0
8
405
3862
1.28
1.28
4.3
3.8
5.7
5.7
mmol/l
0.19
370
3570
54
409
1.36
1.27
6.1
5.4
—
—
—
0
0
8
36
2.24
1.24
4.1
1.6
—
—
—
0
0
14
78
1.82
1.22
1.9
1.8
—
—
—
0
0
10
50
2.02
1.17
1.3
1.1
—
—
—
0
0
20
127
1.60
1.13
1.3
1.2
—
—
—
0
0
43
321
1.37
1.12
1.7
1.3
21.5
27.0
iu/l
0.61
38
271
10
51
1.98
1.12
1.3
1.1
—
—
—
0
0
7
32
2.20
1.08
1.3
1.2
—
—
—
0
0
68
547
1.28
1.08
1.9
1.7
1099.8
1183.8
nmol/l
0.35
54
408
376
3580
1.22
1.05
5.3
4.8
38.0
38.6
mmol/mol
0.54
345
3378
7
34
2.07
1.03
1.0
1.0
—
—
—
0
0
9
47
1.93
1.02
1.2
1.1
—
—
—
0
0
400
3836
1.23
1.02
3.9
3.5
1.4
1.2
mmol/l
2.95
377
3581
7
35
2.01
1.00
1.0
1.2
—
—
—
0
0
7
35
2.01
1.00
1.7
1.3
—
—
—
0
0
9
49
1.85
0.99
2.9
3.0
26.9
38.5
u/ml
—
9
49
9
49
1.85
0.99
1.1
1.1
—
—
—
0
0
7
36
1.96
0.97
1.0
1.3
—
—
—
0
0
13
77
1.71
0.96
1.1
1.2
140.0
236.8
u/ml
—
8
49
9
51
1.78
0.95
1.9
1.4
—
—
—
0
0
6
27
2.24
0.93
1.0
2.2
—
—
—
0
0
12
70
1.73
0.93
1.4
1.3
91.4
120.9
u/ml
—
5
15
19
127
1.52
0.90
1.3
1.2
—
—
—
0
0
13
80
1.64
0.85
1.1
1.2
—
—
—
0
0
17
113
1.52
0.83
2.3
2.0
—
—
—
0
0
26
190
1.39
0.81
1.8
3.2
1.6
1.3
mmol/l
0.15
18
139
95
822
1.19
0.80
1.6
1.5
22.8
21.7
nmol/l
0.28
85
705
13
82
1.60
0.78
1.1
1.4
—
—
—
0
0
36
279
1.31
0.78
1.4
1.3
—
—
—
0
0
12
75
1.62
0.75
1.3
1.5
3613.6
11534.6
e6/l
—
5
52
5
25
2.01
0.73
1.2
1.6
—
—
—
0
0
7
41
1.72
0.70
1.9
1.6
—
—
—
0
0
42
339
1.26
0.69
14.9
14.5
1.1
1.2
inr
—
5
56
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
27
1.86
0.68
1.2
1.1
—
—
—
0
0
10
62
1.63
0.65
1.8
1.3
—
—
—
0
0
5
29
1.73
0.64
1.2
1.2
—
—
—
0
0
5
29
1.73
0.64
1.0
1.6
0.9
0.9
g/l
—
5
29
8
49
1.64
0.62
1.0
1.2
—
—
—
0
0
64
548
1.19
0.62
1.5
1.6
1.5
1.4
%
0.49
55
497
14
98
1.44
0.57
2.7
2.3
1.1
0.7
g/l
0.22
14
90
6
38
1.59
0.54
1.2
1.2
—
—
—
0
0
6
38
1.59
0.54
1.3
1.6
—
—
—
0
0
13
91
1.44
0.53
2.3
2.1
40.4
38.7
g/l
0.73
13
84
6
39
1.54
0.53
1.0
1.0
1.4
1.4
g/l
—
6
34
27
217
1.26
0.49
1.7
1.5
—
—
—
0
0
24
190
1.28
0.49
2.5
2.5
0.1
0.2
e6/l
0.43
24
183
17
128
1.34
0.48
1.4
1.4
—
—
—
0
0
27
218
1.25
0.47
1.6
1.4
—
—
—
0
0
10
68
1.48
0.47
1.3
1.3
—
—
—
0
0
10
68
1.48
0.47
1.3
1.3
—
—
—
0
0
26
210
1.25
0.46
1.6
1.6
—
—
—
0
0
8
56
1.44
0.42
1.4
1.4
—
—
—
0
0
5
33
1.52
0.41
1.2
1.2
—
72.2
—
0
5
0
15
0.00
0.41
0.0
1.1
—
24.8
—
0
15
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
36
417
0.85
0.37
3.5
3.9
28.2
32.9
%
1.44
24
286
11
81
1.37
0.36
1.9
2.9
7.3
8.5
kpa
1.15
11
76
14
108
1.31
0.35
2.1
2.8
9.5
10.0
mg/l
0.21
14
100
9
122
0.73
0.35
1.9
1.6
—
—
—
0
0
32
275
1.18
0.33
6.4
3.5
2.0
1.9
mmol/l
0.03
25
220
10
75
1.34
0.30
3.0
2.1
—
—
—
0
0
47
421
1.13
0.30
1.8
1.5
—
—
—
0
0
8
107
0.74
0.29
1.0
1.2
—
—
—
0
0
401
3945
1.09
0.29
18.3
11.8
40.2
39.9
%
0.30
316
3125
8
63
1.27
0.28
1.3
1.3
—
—
—
0
0
8
64
1.25
0.27
1.3
1.1
—
—
—
0
0
9
76
1.19
0.24
1.0
1.3
—
—
—
0
0
16
133
1.21
0.24
4.1
3.0
51.5
50.2
%
0.06
16
133
18
153
1.18
0.22
3.0
2.0
11.4
11.7
nmol/l
0.07
18
140
5
42
1.19
0.21
1.0
1.2
—
—
—
0
0
5
42
1.19
0.21
1.0
1.2
—
—
—
0
0
5
42
1.19
0.21
1.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
5
43
1.16
0.21
1.2
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
—
—
0
0
11
90
1.23
0.19
1.1
1.1
1.0
2.0
u/ml
—
5
49
18
157
1.15
0.17
1.8
1.6
—
—
—
0
0
35
321
1.10
0.17
2.4
4.1
3.6
22.1
ug/l
0.74
25
254
16
140
1.15
0.15
2.4
2.4
1.6
1.2
%
1.14
16
140
17
190
0.89
0.13
1.4
1.9
—
—
—
0
0
24
220
1.10
0.12
1.3
1.3
123.6
258.5
miu/ml
1.86
11
115
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
47
1.06
0.09
1.2
1.2
—
—
—
0
0
28
262
1.07
0.09
1.1
1.0
—
—
—
0
0
5
48
1.04
0.09
1.2
1.1
—
—
—
0
0
76
736
1.04
0.08
2.1
1.6
495.2
19401074.1
pmol/l
0.78
65
634
6
57
1.05
0.08
1.2
1.2
—
—
—
0
0
26
277
0.94
0.08
1.7
1.5
—
—
—
0
0
48
460
1.05
0.08
1.3
1.6
—
—
—
0
0
6
73
0.82
0.07
1.5
1.8
13.3
13.3
%
—
6
73
28
269
1.04
0.04
3.6
3.5
25.0
21.8
%
0.48
13
104
104
1053
0.98
0.03
1.6
1.5
—
—
—
0
0
24
249
0.96
0.02
1.7
1.5
—
—
—
0
0
14
132
1.06
0.02
5.8
9.1
23.2
24.5
mmol/l
1.50
14
125
18
185
0.97
0.00
2.1
1.7
—
—
—
0
0
22
225
0.98
0.00
1.5
1.8
4.1
2.6
mg/l
0.39
17
159
23
227
1.01
0.00
1.7
1.4
—
—
—
0
0
23
227
1.01
0.00
1.7
1.4
—
—
—
0
0
20
198
1.01
0.00
2.9
2.4
0.5
0.7
ug/l
1.58
13
104
23
228
1.01
0.00
1.7
1.4
—
—
—
0
0
23
228
1.01
0.00
1.7
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
2.6
—
—
—
0
0
5
53
0.94
0.00
1.2
1.5
—
12.9
—
0
5
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
1.2
—
0
8
6
63
0.95
0.00
1.2
1.1
128.8
120.1
%
—
6
56
0
5
0.00
0.00
0.0
1.0
—
76.8
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_VONVILLEBRAND and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_VONVILLEBRAND | 1.504 [1.17, 1.94] | 0.002 |
| Birth year | 0.996 [0.99, 1.0] | 0.303 |
During the follow-up period (1.1.1998 — 31.12.2019), 103 out of 1902 females with D3_VONVILLEBRAND died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_VONVILLEBRAND | 1.609 [1.22, 2.12] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.013 |
During the follow-up period (1.1.1998 — 31.12.2019), 80 out of 821 males with D3_VONVILLEBRAND died.
Mortality risk
Mortality risk for people of age
years, who have D3_VONVILLEBRAND.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.137% | 0.35% |
| 5 | 0.906% | 2.071% |
| 10 | 2.221% | 5.037% |
| 15 | 4.34% | 9.326% |
| 20 | 7.565% | 15.692% |
Relationships between endpoints
↥Index endpoint: D3_VONVILLEBRAND – Von Willebrand disease
GWS hits: 10
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data